MicroRNA-181b Serves as a Circulating Biomarker and Regulates Inflammation in Heart Failure
Table 1
Patients’ clinical data.
Clinical characteristics
ctl (n=31)
DCM (n=41)
ICM (n=31)
Ages (years)
Mean
50.29 ± 7.62
49.31± 8.99
55.26± 7.47
Range
38±65
29±62
29±66
Median
49
50
49
Sex
Men
14(45.2%)
27(65.9%)
21(67.7%)
Women
17
14(34.1%)
10(32.3%)
Active smoker
7(22.5%)
14(34.1%)
16(51.6%)
History of drinking
4(12.9%)
13(31.7%)
4(12.9%)
BUN,mmol/L
4.96± 0.17
7.31± 0.45
7.35± 0.63
Creatinine,umol/L
64.75 ±2.49
86.90±7.54
98.86±15.99
UA,umol/L
299.12±18.52
455.65±22.87
373.95±24.68
ALT,u/L
22.27±2.25
40.09±6.35
81.78±44.95
AST,u/L
21.06±1.70
35.13±3.21
121.68±67.65†
NYHA class
III
21(51.2%)
16(51.61%)
IV
20(48.8%)
15(48.4%)
Diagnosis-related factors
hsCRP,mg/L
2.50±0.53
6.08±1.09
43.7±10.77†
NT-pro-BNP,pg/ml
60.43±6.91
3649.45±909.85
7603.3±3482.96
LVEF,%
64.40±0.99
30.45±1.13
33.39±1.19
LVEDD,mm
47.28±0.68
69.03±1.11
64.48±1.12
Concurrent medication,%
Nitroprusside sodium
65.8
83.9
Beta-blockers
21.9
77.4
ACEI/ARB
60.9
87
Diuretics
82.9
96.7
Digitoxin
63.4
67.7
Aspirin
43.9
51.5
LVEF, left ventricular ejection fraction; LVEDD, left ventricular end diastolic diameter; NYHA class, New York Heart Association class; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blockers; hsCRP, high-sensitivity C-reactive protein. Data are expressed as mean±SEM or number(%); compared with control group; †P<0.05 compared with DCM group.
